Pemvidutide achieves 15.6% weight loss at 48 weeks
Topline results from the MOMENTUM Phase 2 obesity trial of pemvidutide has shown at week 48, subjects receiving pemvidutide achieved mean...
top of page
Browse by category
Search
Altimmune completes dosing in the Phase 2 MOMENTUM trial
Altimmune has completed dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of...
FDA approves Phase II trial for obesity-treating drug pemvidutide
The Food and Drug Administration (FDA) has approved a Phase II clinical trial for investigational obesity-treating drug pemvidutide. The...
Browse by tag
bottom of page